Table 2

Cox proportional hazards models for progression-free survival

CharacteristicsUnivariate analysesMultivariable model
HR (95% CI)P valueHR (95% CI)P value
Age≥65 vs <650.74
GenderFemale vs male0.80
SmokingCurrent vs never/former0.62
ECOG PS2 vs 0–12.10 (1.00 to 4.10) 0 .04 4.83 (1.42 to 16.40) 0 .01
HistologySquamous vs non-squamous0.51
PD-L1 statusPositive vs negative0.56 (0.36 to 0.88) 0 .01 0.48 (0.30 to 0.77) 0 .002
Metastatic sites (N)>2 vs 1–20.13
Brain metsYes vs no0.22
Liver metsYes vs no0.09
Bone metsYes vs no0.05
Line of treatment>2 vs 1–20.84
ICI regimenMono vs dual0.08
Early use of steroidsYes vs no1.80 (1.20 to 2.80) 0 .003 1.88 (1.08 to 3.28) 0 .03
  • P values below the significance threshold are reported in bold.

  • ECOG PS, Eastern Cooperative Oncology Group Performance Status; ICI, immune checkpoint inhibitor.